How Investors Are Reacting To Sanofi (ENXTPA:SAN) Winning First-in-Class EU Nod For Wayrilz [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
thrombocytopenia who are refractory to other treatments, following positive phase 3 LUNA 3 data. This first-in-class approval adds a differentiated, oral immunology therapy to Sanofi's hematology portfolio, potentially strengthening its position in rare immune-mediated diseases and supporting ongoing efforts to shift toward higher-value specialty medicines. We'll now examine how this first-in-class EU approval for Wayrilz could influence Sanofi's existing investment narrative around pipeline execution and specialty care focus. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Sanofi, you need to believe in its pivot toward higher-value specialty medicines and disciplined pipeline execution, while accepting near term uncertainty in R&D outcomes and pricing pressure in vaccines. The EU approval of Wayrilz and fresh Tzield and tolebrutinib updates are relevant to th
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sanofi (NASDAQ:SNY) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- JPM26: Leo Pharma's growth strategy puts a spotlight on rare dermatology diseases [Yahoo! Finance]Yahoo! Finance
- State Street's crypto push, FDA delays review of Eli Lilly GLP-1 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]Seeking Alpha
SNY
Sec Filings
- 1/16/26 - Form 6-K
- 1/9/26 - Form 6-K
- 12/29/25 - Form 6-K
- SNY's page on the SEC website